Report #2826524

Received Feb 17, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: —
Recovered: Unknown
Vaccinated: Dec 7, 2024
Onset: Dec 7, 2024
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	—	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Late 2nd dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too long in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 30-MAY-2023). On 07-DEC-2024, the patient received the 2nd dose of Shingrix. On 07-DEC-2024, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Late 2nd dose). The outcome of the drug dose administration interval too long was unknown. Additional Information: GSK Receipt Date: 13-FEB-2025 The health care professional reported that a patient that was came in for their second dose of shingrix. No further details were obtained from the chatter, only what is shown here in this report. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccination schedule.